Pathios Therapeutics presented clinical development plans for an antagonist of GPR65, a proton-sensing GPCR intended to counter immunosuppression created by acidic tumor microenvironments. The company frames the approach as a way to reprogram immune barriers in “cold” tumors, aiming to support activity of ADC and chemotherapy by disrupting acidity-driven myeloid and T-cell suppression. The strategy reflects ongoing immuno-oncology focus on microenvironment control rather than adaptive immune checkpoints alone, especially where resistance and low baseline immune infiltration remain limiting factors.